 The Phase 3 Voyage 1 trial evaluated the efficacy and safety of Goosalcumab for psoriasis over 4 years, showing high response rates maintained through Week 204 using different methodologies including pre-specified treatment failure rules, non-responder imputation, and as observed analysis. No new safety signals were identified. This article was authored by Christopher E. M. Griffiths, Kim A. Tapp, Michael Song, and others.